CSPC Wins "Private Enterprises of Scientific and Technological Innovation" Title from ACFIC

On the morning of October 19, 2023, the National Private Enterprise Scientific and Technological Innovation and Standard Innovation Conference was held in Changsha. During the conference, the All-China Federation of Industry and Commerce (ACFIC) released the list of national private enterprises for their scientific and technological innovation.

Only 20 enterprises from across the country made it to the list, and CSPC was among them.

In the first half of 2023, ACFIC initiated the process for private enterprises to apply for the honor of technology innovation bases. CSPC, recommended by the Hebei Federation of Industry and Commerce, submitted materials to apply for this honor. After rigorous evaluation, we proudly represented Hebei province as one of the "Private Enterprises of Scientific and Technological Innovation".

During the conference, ACFIC also revealed the top 500 private enterprises by R&D investment in 2023, where CSPC, building upon the achievements from the previous year, moved up to the 40th position and ranked 2nd in the pharmaceutical manufacturing industry.

CSPC is one of the earliest companies in China to engage in innovative drug research and development, with the investment in R&D continually increasing over the years. In 2022, CSPC invested approximately RMB 4 billion in R&D. In the first half of this year, our R&D investment exceeded RMB 2.3 billion, marking a 22.3% year-on-year growth.

Currently, CSPC has established five major R&D centers worldwide, with a well-structured internal research organization. We have also received numerous national-level research honors, including being a National Center for Post-Doctoral Programme, a National 863 Industrialization Base, a National Enterprise Technology Center, a National Innovative Enterprise, a National Intellectual Property Demonstration Enterprise, a National Key Laboratory for New Drug Formulation and Excipients, and a National and Local Joint Engineering Laboratory for Chiral Drug Development, among others. Additionally, we have received ten provincial-level science and technology platform titles, including the Hebei Province Formulation Technology Innovation Center and the Hebei Province Antibiotics Technology Innovation Center.

CSPC actively participates in major national research projects and has undertaken dozens of national-level research programs, including three "863" projects, two "973" projects, one National Key R&D Program project, one international science and technology cooperation project, 55 significant new drug development projects, and 13 major industrialization projects supported by the National Development and Reform Commission and the Ministry of Industry and Information Technology.